Evidence map›Paper›PMID 33925510›Full record

ArticleInternational journal of molecular sciences2021

Serum APOA4 Pharmacodynamically Represents Administered Recombinant Human Hepatocyte Growth Factor (E3112).

Sotaro Motoi, Mai Uesugi, Takashi Obara, Katsuhiro Moriya, Yoshihisa Arita, Hideaki Ogasawara, Motohiro Soejima, Toshio Imai, Tetsu Kawano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Understanding HDL Metabolism and Biology Through In Vivo Tracer Kinetics.Arteriosclerosis, thrombosis, and vascular biology · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sotaro MotoiEisai Product Creation Systems, KAN Product Creation Unit, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.
Mai UesugiMedicine Creation, Neurology Business Group, Translational Medicine Department, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.
Takashi ObaraMedicine Creation, Neurology Business Group, Translational Medicine Department, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.
Katsuhiro MoriyaKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan.
Yoshihisa AritaKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan.
Hideaki OgasawaraKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan.
Motohiro SoejimaEisai Product Creation Systems, KAN Product Creation Unit, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.
Toshio ImaiKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan.ORCID 0000-0002-4022-1962
Tetsu KawanoKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan.
KAN Research Institute · JPEisai (Japan) · JP

Funding

Japan Agency for Medical Research and Development 16im0110801h0006
6 · The paper itself

Abstract

backgroundHepatocyte growth factor (HGF) is an endogenously induced bioactive molecule that has strong anti-apoptotic and tissue repair activities. In this research, we identified APOA4 as a novel pharmacodynamic (PD) marker of the recombinant human HGF (rh-HGF), E3112.

methodsrh-HGF was administered to mice, and their livers were investigated for the PD marker. Candidates were identified from soluble proteins and validated by using human hepatocytes in vitro and an animal disease model in vivo, in which its c-Met dependency was also ensured.

resultsAmong the genes induced or highly enhanced after rh-HGF exposure in vivo, a soluble apolipoprotein,

conclusionsAPOA4 was identified as a soluble PD marker of rh-HGF with c-Met dependency. It should be worthwhile to clinically validate its utility through clinical trials with healthy subjects and ALF patients.

Indexed as

AnimalsApolipoproteins ABiomarkers, PharmacologicalCells, CulturedGene Expression RegulationHepatocyte Growth FactorHepatocytesHumansLiverLiver Failure, AcuteMaleMiceMice, Inbred BALB CProto-Oncogene Proteins c-metRecombinant Proteinsapolipoprotein A-IVApolipoproteins ABiomarkers, PharmacologicalHepatocyte Growth FactorHGF protein, humanProto-Oncogene Proteins c-metRecombinant ProteinsALFAPOA4c-MetFasrh-HGF

Identifiers

PMID33925510
PMCPMC8123842
OpenAlexW3159054754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.